J&J Deserves More Respect from Wall Street

Posted On December 12, 2016 By OrthoSpineNews In Financial /

By RESHMA KAPADIA – December 10, 2016

Many investors hang on to Johnson & Johnson shares for the same reason they stock their cabinets with the company’s Band-Aids and baby shampoo: comfort and safety. Johnson & Johnson offers a diverse business mix, including pharmaceuticals, medical devices, and consumer products; a $40 billion cash kitty; and steady, mid-single-digit earnings growth. Add a dividend yield near 3%, and the stock soothes many a portfolio, especially when markets are roiled.

J&J’s shares (ticker: JNJ) are up 8% this year, to a recent $111, but down 5% since Donald J. Trump’s election. Trump has vowed to reduce drug prices, but J&J is less susceptible to changes in pricing than its peers. Moreover, the New Brunswick, N.J.–based company could prosper as a result of Trump’s plans to lower corporate taxes.

Internally, J&J is making substantial improvements in its consumer and medical-device businesses. In addition, reduced concern about competition for Remicade, its blockbuster rheumatoid arthritis treatment, could help bolster the stock. Some analysts see J&J shares rallying to the mid-$130s in the next year, delivering a total return around 20%.

“J&J is misunderstood as a defensive stock,” says Micky Jagirdar, an analyst for Ariel Global fund, which owns shares of the drugmaker. “While it grows at only a single-digit pace, its diverse businesses make that growth more sustainable for a longer time.”

Johnson & Johnson is expected to earn $18.6 billion this year, or $6.71 a share, an increase of 8% over last year, on a 3% jump in revenue, to $72.1 billion. Wall Street sees earnings per share rising 6% in 2017, to $7.13, on revenue of $75.5 billion.

Founded in 1886 as a surgical-dressing concern, J&J now generates 45% of its revenue and almost 60% of its operating profit from pharmaceuticals. Medical devices produced a bit more than a third of revenue and operating profit last year, while the company’s iconic consumer business contributed just under 20% of revenue and 9% of profit.

READ THE REST HERE

AAEAAQAAAAAAAAifAAAAJDkxMGJkMGQwLTI3MTktNDA3NS1iM2Y5LTdjZjhjYTVhYjRiNw.jpg

Axiomed is Raising Interest from Silicon Valley

Posted On December 12, 2016 By OrthoSpineNews In Spine /

BOSTON, MA (PRWEB) DECEMBER 09, 2016

Aditya Humad, Acting CFO of AxioMed and Managing Partner of KICVentures, is pleased to announce that in addition to Australia, Europe, and the United States, Axiomed is now gaining interest from Silicon Valley. “It was satisfying to complete the due diligence required to assure interest in this technology.”

Mr. Humad went on to say that, “We expect interest to continue to rise as AxioMed completes its cleanroom assembly to begin manufacturing the cervical and lumbar viscoelastic disc for international distribution to meet an anticipated high demand.” AxioMed completed its IDE in August 2016 and is preparing a submission to the FDA for the clearance of its viscoelastic lumbar disc.

Dr. Kingsley R. Chin, Acting CEO of AxioMed and Managing Partner at KICVentures has been spending more time in Silicon Valley and is quoted as saying, “I feel I share a lot in common with the entrepreneurs in Silicon Valley. I have a tremendous respect for their accomplishments in a broad range of technologies and I feel they have a lot of respect for my knowledge, track record, and experience in health technology. Experts in Silicon Valley have expressed the importance of the potential disruption the seems eminent within healthcare. Time and time again, I get the feedback that AxioMed’s viscoelastic technology seems intuitive over all other existing technologies for spine surgery. They also feel that the clinical and biomechanical results so far are very convincing. I expect interest to build as we demonstrate continued progress.”

About AxioMed
Founded in 2001, AxioMed (http://www.axiomed.com/) began its journey of exhaustively proving the Freedom® Disc through clinical studies in the USA and Europe, research, development and testing. In 2014, KICVentures recognized the disc’s enormous potential and acquired the company into their healthcare portfolio. AxioMed owns an exclusive viscoelastic material license on its proprietary Freedom Disc technology.

Tissue Regenix Group plc – DermaPure secures GPO agreement with Premier, Inc.

Posted On December 12, 2016 By OrthoSpineNews In Biologics /

Leeds, 06 December 2016 – Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”) the regenerative medical devices company today announces Tissue Regenix Wound Care, Inc. has secured a Group Purchasing Organisation (GPO) contract with Premier Inc., a leading healthcare improvement company.

DermaPure has been awarded this contract under a ‘Breakthrough Technology Agreement’, which is awarded by the GPO after a thorough four step review process is completed and it is determined that the technology offers unique attributes to the other available treatment options.

The Premier alliance is comprised of approximately 3,600 U.S. based hospitals and 120,000 other healthcare providers which will now have contracted access to DermaPure®.

Antony Odell, CEO, Tissue Regenix Group plc commented: “Approval under Premier’s Breakthrough Technology Agreement marks a significant milestone for DermaPure®. This confirms the unique characteristics of our patented dCELL® Technology, the powerful clinical evidence we have collected, and the remarkable outcomes it achieves in real world clinical situations.”

For more Information:

Tissue Regenix Group plc Caitlin Pearson Corporate Communications Officer	Tel: 0330 430 3073
Jefferies International Ltd Simon Hardy / Harry Nicholas	Tel: 020 7029 8000

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®’) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States – ‘Tissue Regenix Wound Care Inc.’, as part of its commercialisation strategy for its dCELL® technology platform.

William Rhoda Joins SeaSpine as General Manager of Process Innovation and Development

Posted On December 12, 2016 By OrthoSpineNews In Spine /

CARLSBAD, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that William Rhoda has joined the Company as General Manager of Process Innovation and Development.

In this newly created position, Mr. Rhoda will establish and lead a small, focused office in eastern Pennsylvania that will provide additional product development and process improvement resources and bring even more focus to surgeon and patient needs. This office will also serve as a local training and education site for surgeons and distributors in the Eastern United States. Mr. Rhoda will report directly to Keith Valentine, President and Chief Executive Officer.

Mr. Rhoda has more than 20 years of experience in the spinal implant market. He started his career in orthopedics with Synthes Spine and later became a founding member of Globus Medical, where he served as the Vice President of Product Development. While at Globus, he conceived and implemented a rapid product development process that dramatically shortened the time from concept to market introduction of new products.

“SeaSpine is a dynamic organization that has dramatically improved its product development process through both quality and output during the past year,” said Mr. Rhoda. “I am excited to join the team and leverage my experience to further reduce the time to market as we continue to drive innovation and put SeaSpine firmly on the map of innovators in the spine market.”

“I am excited to welcome Bill to our leadership team and look forward to his contributions to drive faster innovation at SeaSpine,” said Keith Valentine. “I am confident that he will be instrumental in adding energy and responsiveness to our engineering effort and keeping us laser-focused on the needs of the surgeon and our sales team.”

About SeaSpine
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development helps SeaSpine to offer its surgeon customers a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.

Forward-Looking Statements
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: Mr. Rhoda’s ability to shorten time-to-market, drive faster innovation and position SeaSpine as an innovator in the spine market. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: Mr. Rhoda’s ability to transition in a timely manner, if at all, and to integrate into SeaSpine’s existing infrastructure, including his ability to collaborate successfully with SeaSpine’s existing product development team; Mr. Rhoda’s ability to conceive and implement a rapid product development process at SeaSpine and his ability to shorten the time from concept to market introduction of new products; surgeons’ willingness to adopt new products resulting from such process, including as a result of failure to demonstrate adequate safety or efficacy, whether as a result of rapid development or otherwise; unexpected expense associated with the new Pennsylvania office; and other risks and uncertainties more fully described in our news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.

Tiny HD Cameras Have Revolutionized Knee Surgery, Doctors Claim

Posted On December 12, 2016 By OrthoSpineNews In Sports Medicine /

December 9, 2016 – Filed Under: Dr. Max Gomez, Knee Surgery, MRI, Mt. Sinai Health System

NEW YORK (CBSNewYork) — Tiny hi-def cameras have been changing everything from home videos to selfies, but new technology has legitimately revolutionized medical procedures.

As CBS2’s Dr. Max Gomez explained, a new camera may actually replace MRIs and even some surgeries, especially in the knees.

If you’ve ever injured your knee it can be hard to tell exactly what’s causing the pain, so the doctor usually send you for an expensive MRI and maybe an arthroscopy in the O.R. to take a look inside. But what if you could do a scope in the doctor’s office cheaper and safer.

Lemouchi Soufinae injured his knee in a car accident two years ago. Since then he hasn’t been able to play his beloved soccer, because of the pain in his knee.

“Can’t walk more than three blocks, have to lay down, have trouble sleeping at night, lot of strong pain,” he said.

Two MRIs later, it still wasn’t completely clear what was causing his knee pain.

Like Lemouchi, Liz Meris has been having severe knee pain.

“Couldn’t kneel or straighten without pain, can’t get out of car, swelling in back of knee, hurts to walk, feels unstable,” she said.

Worse yet, Liz is claustrophobic in an MRI

“Hate em, I’m claustrophobic. I’m out, I’m in, I’m out again,” she said.

The next is usually a trip into the operation room to look around by sticking a scope in the knee. It’s expensive and requires anesthesia.

Why not do that in the office, under a local anesthesia?

Thanks to a tiny scope with a hi-def camera on the tip, doctors can do in the office what once took a trip to the O.R.

READ THE REST HERE

New Orthopedic Device Technology Moves From Lab Toward Operating Room With Help From Philadelphia-Based Start-Up OrthoMend Research, Inc.

Posted On December 9, 2016 By OrthoSpineNews In Extremities, Financial /

PHILADELPHIA, Dec. 9, 2016 /PRNewswire-USNewswire/ — A platform of orthopedic device technologies developed by researchers from Temple University are moving one step closer to becoming viable options for repairing broken bones and orthopedic applications. OrthoMend Research, Inc., a start-up company from Philadelphia, PA., recently acquired the exclusive license for these novel absorbable bone fixation and regenerative repair technologies and plans to develop them for commercial use. The company has leased space within the University City Science Center.

“OrthoMend Research, Inc. has licensed exclusive commercial rights from Temple University for Nano-Diamond technology in bone fixation which has the potential to evolve current therapies to fix, repair and regenerate bones and orthopedic “drug delivery applications,” OrthoMend Research, Inc. CEO Joseph P. Connell said. “It is our desire to commercialize the technology to improve clinical outcomes, reduce costs and alleviate pain and suffering for our patients.”

“OrthoMend Research represents the important role startups have in our commercialization process by bringing together the inventors, technology and business leadership to advance this orthopedic device to patients in need,” said Stephen Nappi, associate vice president for technology commercialization and business development at Temple.

“We are very excited to begin our next phase by manufacturing and testing the devices. We plan to make considerable contributions to clinical outcomes and improve patient’s lives by repairing broken bones without leaving hardware behind in a patient’s body.” said Connell.

Peter Lelkes, chair of bioengineering and director of the Institute for Regenerative Medicine and Engineering at Temple is equally enthusiastic about the licensing agreement and the potential for collaborative research and development opportunities.

“The licensing of our invention to OrthoMend Research is an important milestone in our efforts to translate our basic research from the bench to the bedside and will, without a doubt, result in commercial products that will benefit patients around the globe,” Lelkes said.

About OrthoMend Research: OrthoMend Research, Inc. is an emerging Regenerative Orthopedic Device Company pioneering new technologies intended to revolutionize bone fixation after orthopedic, surgical and trauma situations. OrthoMend Research, Inc. is involved with commercializing technologies licensed from Temple University for an absorbable suite of bone fixation and drug delivery devices. We will develop, test and launch absorbable screws, pins and possibly plates to repair the millions of broken bones occurring each year. We are steadfast to be the leader in orthopedic devices delivering real-world technologies to impact the lives of those in need. For more information, visit www.orthomend.com

About Temple University’s Department of Bioengineering: Founded in January 2012, the Dept. of Bioengineering in the College of Engineering has grown significantly in the past four years to about 300 undergraduate students, nearly 50 graduate students, 11 core faculty members and two dozen affiliated faculty from across the entire university. The Department is the home of a first-rate, nationally and internationally recognized bioengineering research enterprise that is supported by extramural funds from NIH, NSF, DoD and others. Its newly renovated, state-of-the-art research facilities (ca. 20,000 square feet) attract graduate students, postdocs, visiting scientists and scores of undergraduate students who pursue exciting basic and translational bioengineering research.

News media contacts:
Joseph P. Connell, CEO, OrthoMend Research, Inc., 910-233-0806, jpconnell1@gmail.com

SOURCE Temple University

Biomatlante invests in innovative solutions for active healing through orthobiologics

Posted On December 9, 2016 By OrthoSpineNews In Biologics /

NANTES, FRANCE (PRWEB) DECEMBER 09, 2016

Coordinated by INSERM (Institut National de la Santé et de la Recherche Médicale) and with the support of the E.U., the REBORNE Program sought to establish the feasibility, relevance and efficacy of the association of MBCP+™*, a synthetic bone graft manufactured by Biomatlante made from MBCP™ Technology, and Mesenchymal Stem Cells (MSCs)1.

REBORNE was a 12 multi-center clinical trials conducted over 8 European countries using advanced biomaterials and cells from autologous sources, as human mesenchymal stem cells from bone marrow, offering great potential for active bone regeneration. Biomatlante successfully went through a stringent selection process, after three years of experiences with the support of ANR (Agence Nationale de la Recherche)², prior to becoming the partner of choice of the European consortium as supplier of the bone graft matrix. A large consortium of 24 participants, with world class laboratories and GMP-cells manufacturing facilities and hospitals, collaborated to reach these ambitious clinical goals.

This program demonstrated the efficacy of expanded MSCs combined with the osteogenic matrix MBCP™ technology for bone tissue engineering in bone regeneration, both from a regulatory, scientific and clinical standpoint. The Reborne project demonstrated the osteogenic and osteoinductive properties of the association of MSCs and MBCP™ Technology3,4,5,6,7 with a high rate of clinical success, particularly in the treatment of long bone non-unions (92%).

Building on these successes, Reborne has now been extended to attempt to provide the same clinical excellence at an affordable price by combining the same MBCP™ Technology matrix with autologous concentrated bone marrow aspirate. Clinical trials are expected to begin in the next few months.

About BIOMATLANTE, Experts in Bone Regeneration
Based near Nantes, France, Biomatlante specializes in synthetic biomaterials for bone regeneration and is a world leader in bone graft technologies, selling its products in over 50 countries. Biomatlante’s products are routinely used in orthopedics and trauma surgery, in spine and dental surgery. BIOMATLANTE strives to integrate a strategy of strong innovation and product development required to meet and exceed the needs of today’s market. Our R&D collaborates closely with universities and research centers across the world, bringing together competences in innovation, technological transfers of new biomaterials, surgical technologies and providing the intellectual protection required to foster long-term projects.

About MBCP™ Technology*, Worldwide Reference in Synthetic Bone Graft
The unique 3-step manufacturing process developed by BIOMATLANTE confers its core MBCP biphasic HA/ ß-TCP technology unique properties for hard tissue regeneration. Its micro-macroporous structure mimics that of human bone and provides an ideal osteogenic matrix for bone regeneration in general and tissue engineering in particular.

About REBORNE, Regenerating Bone Defects Using New Biomedical Engineering Approaches
The objective of REBORNE is to develop new biomaterials that stimulate bone tissue formation with a view to correcting bone regeneration defects in orthopedic and maxillofacial surgery. Biomaterials, combined with the use of stem cells, are interesting alternatives to biological grafts.

About INSERM, French National Institute of Health and Medical Research
Founded in 1964, INSERM is a public scientific and technological institute that operates under the joint authority of the French Ministry of Health and French Ministry of Research. Its researchers are tasked with studying all diseases, from the most common to the most rare, through their work in biological, medical and public health research.

1.    Reborne: HEALTH 20091.4.2-241879 (Regenerating Bone Defects using new biomedical engineering approaches)
2.    Daculsi et al, Association of cells and biomaterials for bone reconstruction, IRBM 32 (2011) 76-79
3.    Brennan MÁ, Renaud A, Amiaud J, Rojewski MT, Schrezenmeier H, Heymann D, Trichet V, Layrolle P. Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate. Stem Cell Res Ther. 2014 Oct 13;5(5):114. doi: 10.1186/scrt504.
4.    Gómez-Barrena E, Rosset P, Muller I, Giordano R, Bunu C, Layrolle P, Konttinen YT, Luyten FT. Bone regeneration: stem cell therapies and clinical studies in Orthopaedics and traumatology. J Cell Mol Med. 2011 Jun; 15(6):1266-1286.
5.    Gomez-Barrena E, Rosset P, Lozano D, Stanovic J, Ermthaller C, Gebhard F. Bone fracture healing: cell therapy in delayed unions and non-unions. Bone. 2015 Jan; 70C:93-101
6.    Gomez-Barrena et al. Non-unions in tibia, femur and humerus safely healed with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric trial. 2016 (in press).
7.    Miramond, T., Corre, P., Borget, P., Moreau, F., Guicheux, J., Daculsi, G., & Weiss, P. (2014). Osteoinduction of biphasic calcium phosphate scaffolds in a nude mouse model. J Biomater Appl. 2014 Oct; 29(4):595-604

For further information about BIOMATLANTE and its technologies, please visit http://www.biomatlante.com

This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use

UNITED-STATES-CAPITOL-BUILDING-ROCKFORD-ADVOCATE-GLASSDOOR-637x400.png

21st Century Cures Act: Impacts on the US Medical Device Market

Posted On December 9, 2016 By OrthoSpineNews In Regulatory /

December 08, 2016 by Stewart Eisenhart

EMERGO SUMMARY OF KEY POINTS:

New legislation significantly impacting FDA oversight of US medical device and drug markets has passed Congress and is awaiting President Obama’s signature.
The 21^st Century Cures Act would establish a priority review program for breakthrough devices, loosen some device clinical trial requirements and clarify how and whether to regulate medical software.
Critics of the new bill warn that efforts to streamline FDA regulations may end up allowing some devices into the US market without proper vetting, causing public health issues.

As legislation targeting a broad swath of US healthcare regulations awaits President Barack Obama’s signature after passage in the US Congress, effects of the pending law on registration and oversight of medical devices in the country will be significant.

The 21^st Century Cures Act, which has garnered rare bipartisan support in Congress and is heavily backed by pharmaceutical and medical device industry lobbyists, would fast-track “breakthrough” and novel device registrations at the FDA, as well as alter clinical investigation requirements of manufacturers. Critics of the proposed legislation, however, warn of public health repercussions if FDA regulations of medical devices are made too lax.

Prioritizing “breakthrough” devices

Among the substantial changes to FDA medical device regulation included in the 21^st Century Cures Act is a proposal to require the agency to set up a priority review program for “breakthrough” devices, or for devices targeting diseases for which no FDA-cleared or approved alternatives are available. The program would build upon a framework already in place at the agency for registration of such devices.

Under the program, a manufacturer or sponsor may request priority review designation before submitting its FDA registration application. The bill would authorize the Secretary of the US Department of Health and Human Services to develop and issue additional guidelines specifying parameters and requirements of the program.

READ THE REST HERE

Bodycad Awarded Key US Patents for Improving Accuracy, Reproducibility and Speed for 3D Imaging in Orthopaedic Applications

Posted On December 9, 2016 By OrthoSpineNews In Regulatory /

QUEBEC CITY, Dec. 8, 2016 /PRNewswire/ — Bodycad announced it has been awarded two key US patents for improving the accuracy, reproducibility and speed for 3D constructs via MRI and CT images in long and small bone orthopaedic applications. These patents are critical to the company’s proprietary approach to creating personalized orthopaedic restorations based on each patient’s distinct anatomy.

To create personalized orthopaedic restorations, the company harnesses the world’s first suite of orthopaedic CAD/CAM software. This technology, along with individual patient imagery, is critical to Bodycad’s Personalized Restoration Evaluation Process (PREP).

“We are pleased to have the United States Patent and Trademark Office award these important and innovative patents to our library of intellectual property,” stated Jean Robichaud, Founder and President of Bodycad. “These patents are further evidence of our technology’s remarkable accuracy which is essential when creating a personalized orthopaedic restoration.”

Bodycad currently has numerous additional patents pending as well as an extensive collection of existing industrial design patents, copyrights and trademarks.

For more information, please visit www.bodycad.com.

ABOUT BODYCAD

Bodycad is developing personalized orthopaedic restorations to overcome the limitations of off-the-shelf, standardized implants. With its proprietary Personalized Restoration Evaluation Process (PREP), it enables surgeons to provide patient-specific solutions with a previously unavailable conformity to every patient’s distinct anatomy. This transformative approach will allow mainstream customization with the goal of optimizing fit, durability and comfort. The privately held company was founded in 2011 and is headquartered in Quebec City, Canada with offices in the United States. Investors include Beaudier, Inc. (Montreal, Canada). ROBIC is patent counsel to Bodycad.

CONTACT
Andrew McLeod
Chief Commercial Officer
andy@bodycad.com

Logo – http://photos.prnewswire.com/prnh/20160407/352645LOGO

SOURCE Bodycad

Medicrea to Host Key Opinion Leader Breakfast in New York City for Investors Focused on Advances in the Personalized Spine Market

Posted On December 8, 2016 By OrthoSpineNews In Spine /

December 08, 2016

LYON, France & NEW YORK–(BUSINESS WIRE)–The MEDICREA Group (Alternext Paris: FR0004178572 – ALMED), worldwide leader pioneering the development and manufacture of personalized analytical services and implant solutions for the treatment of complex spinal conditions, today announced that it will host a Key Opinion Leader breakfast in New York City for investors focused on advances in the personalized spine market at 8:00 am Eastern Time on Thursday, December 15, 2016.

The meeting will feature keynote presentations by spine surgeon KOLs Nicholas Qandah, DO, from the Mohawk Valley Health System, and Themistocles Protopsaltis, MD, from NYU Langone Medical Center, Bellevue Hospital, who will provide an overview of the complex spine market and discuss current and novel approaches to treating complex spinal conditions.

Members of the Medicrea management team will provide an overview of the Company’s UNiD™ personalized spinal technology platform of analytical services and patient-specific implants for the complex spine market, which received the first ever FDA Clearance for a personalized spinal treatment modality.

Dr. Nicholas Qandah is a complex spine specialist and the Director of Neurosurgery at the Mohawk Valley Health System in New Hartford, NY. Dr. Qandah was previously the Director of the Complex Spine Program for Neurosurgery and an Assistant Professor of Neurosurgery for the Residency Program at Virginia Tech Carilion Clinic in Roanoke, VA. In addition to general neurosurgery, Dr. Qandah treats patients with back and neck pain, degenerative disc disease, spinal stenosis, and herniated discs. He has special interest and expertise in minimally invasive spine surgery, complex spine surgery, and surgery for scoliosis. Dr. Qandah is a Fellow of the American College of Osteopathic Surgeons and a member of the Association for Collaborative Spine Research. Dr. Qandah completed his Neurosurgical Residency training at the Virginia Tech Carilion Clinic and was subsequently awarded the AO Complex Spine Fellowship in Orthopedics and Neurosurgery at the prestigious Harborview Medical Center at the University of Washington in Seattle, WA.

Dr. Themistocles Protopsaltis is an orthopedic spine surgeon at NYU Langone Medical Center and the Hospital for Joint Diseases. He serves as Director of Adult Spinal Deformity Surgery and Director of the Orthopaedic Spine Service at Bellevue Hospital Center in New York, NY. He is also an Assistant Professor in the Department of Orthopedic Surgery at NYU School of Medicine. Dr. Protopsaltis is board certified in orthopedic surgery and is actively involved in many research areas. Some of his interests include cervical and thoracolumbar spinal deformity, cervical spondylotic myelopathy surgical outcomes, and proximal junctional kyphosis avoidance in adult scoliosis patients. He is a member of the International Spine Study Group, comprised of leading physicians from multiple academic centers studying cervical and thoracolumbar spinal deformity surgery. He is also a fellow of the American Academy of Orthopaedic Surgeons. Dr. Protopsaltis earned his medical degree at the Columbia University College of Physicians and Surgeons and completed his orthopedic surgery residency at New York Presbyterian Hospital. He has completed a spine surgery fellowship at NYU Langone Hospital for Joint Diseases.

The event is intended for investors, analysts, investment bankers, and business development professionals only. If you would like to attend in person, please contact Mac MacDonald at 212-915-2567 or via e-mail at Mac@LifeSciAdvisors.com to reserve a place.

A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20161215/reg.jsp and within the Investors section of the Company’s website at www.medicrea.com.

About MEDICREA (www.medicrea.com)

MEDICREA specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, MEDICREA leads the design, integrated manufacture, and distribution of 30+ FDA approved implant technologies, utilized in over 100k spinal surgeries to date. Operating in a $10 billion marketplace, MEDICREA is an SME with 150 employees worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient- specific implants.

By leveraging its proprietary software analysis tools with big data and deep learning technologies supported by an expansive collection of clinical and scientific data, MEDICREA is well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R.

For further information, please visit: medicrea.com.

Connect with MEDICREA:
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

MEDICREA is listed on ALTERNEXT Paris ISIN: FR 0004178572 – Ticker: ALMED

Contacts

MEDICREA
Denys Sournac
Founder, Chairman and CEO
dsournac@medicrea.com
or
Fabrice Kilfiger, +33 (0)4 72 01 87 87
Chief Financial Officer
fkilfiger@medicrea.com

Month: December 2016

Contacts